UBS AM
ABUS icon

UBS AM’s Arbutus Biopharma ABUS Stock Holding History

UBS AM’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.25M Sell
261,052
-577,158
-69% -$2.53M ﹤0.01% 2269
2026
Q1 		$3.77M Sell
838,210
-52,688
-6% -$230K ﹤0.01% 1705
2025
Q4 		$4.29M Buy
+890,898
New +$4.01M ﹤0.01% 1538
2025
Q3 		– Sell
-1,072,744
Closed -$3.31M – 2277
2025
Q2 		$3.31M Buy
1,072,744
+957,794
+833% +$3.18M ﹤0.01% 1907
2025
Q1 		$401K Buy
114,950
+11,007
+11% +$36.7K ﹤0.01% 2530
2024
Q4 		$340K Sell
103,943
-91,900
-47% -$338K ﹤0.01% 2602
2024
Q3 		$754K Buy
+195,843
New +$751K ﹤0.01% 2512

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS AM's ABUS Position: Q2 2026 in Review

UBS AM reduced its Arbutus Biopharma (ABUS) stake by 69% in Q2 2026, selling an estimated $2.53M and leaving 261,052 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #2269.

UBS AM first reported a position in ABUS in Q3 2024 and has held it in 7 quarters since. The position peaked at $4.29M in Q4 2025. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • UBS AM held 261,052 shares of Arbutus Biopharma worth $1.25M as of Q2 2026.
  • UBS AM sold 577,158 Arbutus Biopharma shares in Q2 2026, an estimated $2.53M.
  • Arbutus Biopharma made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2269 holding.
  • UBS AM first reported a position in Arbutus Biopharma in Q3 2024 and has held it in 7 quarters since.
  • UBS AM's Arbutus Biopharma position peaked at $4.29M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.